JP2019510739A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510739A5
JP2019510739A5 JP2018540415A JP2018540415A JP2019510739A5 JP 2019510739 A5 JP2019510739 A5 JP 2019510739A5 JP 2018540415 A JP2018540415 A JP 2018540415A JP 2018540415 A JP2018540415 A JP 2018540415A JP 2019510739 A5 JP2019510739 A5 JP 2019510739A5
Authority
JP
Japan
Prior art keywords
compound
composition according
mammal
gfral
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018540415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510739A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/074809 external-priority patent/WO2017147742A1/en
Publication of JP2019510739A publication Critical patent/JP2019510739A/ja
Publication of JP2019510739A5 publication Critical patent/JP2019510739A5/ja
Pending legal-status Critical Current

Links

JP2018540415A 2016-02-29 2016-02-29 Gfral受容体療法 Pending JP2019510739A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/074809 WO2017147742A1 (en) 2016-02-29 2016-02-29 Gfral receptor therapies

Publications (2)

Publication Number Publication Date
JP2019510739A JP2019510739A (ja) 2019-04-18
JP2019510739A5 true JP2019510739A5 (https=) 2019-05-30

Family

ID=59742416

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540415A Pending JP2019510739A (ja) 2016-02-29 2016-02-29 Gfral受容体療法

Country Status (4)

Country Link
EP (1) EP3423094A4 (https=)
JP (1) JP2019510739A (https=)
CN (1) CN108697795A (https=)
WO (1) WO2017147742A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103533951B (zh) 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20170299608A1 (en) * 2016-03-04 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
PE20190126A1 (es) 2016-03-31 2019-01-17 Ngm Biopharmaceuticals Inc Proteinas de union y metodos de uso de las mismas
EP3526346A1 (en) * 2016-10-12 2019-08-21 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
EP3870211B1 (en) 2018-10-22 2025-01-08 Janssen Sciences Ireland Unlimited Company Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
US12544427B2 (en) 2019-10-04 2026-02-10 Amgen Inc. Use of GDF15 for treating cardiometabolic syndrome and other conditions
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
WO2021246773A1 (ko) * 2020-06-04 2021-12-09 재단법인대구경북과학기술원 Gfral 길항 항체 및 이의 용도
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CA3215737A1 (en) * 2021-03-31 2022-10-06 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
US20240368286A1 (en) * 2021-06-30 2024-11-07 Shanghai Jmt-Bio Technology Co., Ltd. Anti-gfral antibody and application thereof
CN118580334A (zh) * 2023-03-03 2024-09-03 北京志道生物科技有限公司 一种多肽分子
IT202300006387A1 (it) * 2023-03-31 2024-10-01 Univ Degli Studi Roma La Sapienza Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica
CN116444667B (zh) * 2023-06-13 2023-09-01 上海驯鹿生物技术有限公司 一种靶向gdf15的全人源抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1506215B1 (en) * 2002-03-05 2016-11-30 Genentech, Inc. Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
US20100278843A1 (en) * 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN103533951B (zh) * 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
CN102321173B (zh) * 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
CA2896076C (en) * 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
WO2017121865A1 (en) * 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof

Similar Documents

Publication Publication Date Title
JP2019510739A5 (https=)
JP2020536109A5 (https=)
JP2012525128A5 (https=)
JP2016512213A5 (https=)
PE20220938A1 (es) Compuestos agonistas de gipr
JP2019506841A5 (https=)
JP2022513420A5 (https=)
JP2018515088A5 (https=)
RU2015127780A (ru) Агонисты рецепторов глюкагона/glp-1 для лечения ожирения
RU2018107047A (ru) Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения
JP2016527286A5 (https=)
JP2016539096A5 (https=)
JP2012500006A5 (https=)
JP2017113019A5 (https=)
JP2014221758A5 (https=)
JP2017510567A5 (https=)
JP2018535948A5 (https=)
JP2017500018A5 (https=)
JP2016537340A5 (https=)
JP2017522903A5 (https=)
JP2016020389A5 (https=)
FI3569620T3 (fi) Ihmisen cgrp-reseptoria sitovat vasta-aineet
JP2016519650A5 (https=)
JP2015522252A5 (https=)
JP2023065390A (ja) 治療用抗cd40リガンド抗体